Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/23/16 → 6/23/19 |
Funding
- Amgen, Inc. (Prot #20130232)
Prot #20130232: A Phase 1b/3 Multicenter, Randomized, Open-label Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Agulnik, Mark (PD/PI)
Project: Research project